BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 18270134)

  • 1. Routine use of the direct thrombin inhibitor bivalirudin for off-pump coronary artery bypass grafting is safe and effective.
    Palmer GJ; Sankaran IS; Sparkman GM; Koster A; Dyke CM; Ebra G
    Heart Surg Forum; 2008; 11(1):E24-9. PubMed ID: 18270134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study.
    Smedira NG; Dyke CM; Koster A; Jurmann M; Bhatia DS; Hu T; McCarthy HL; Lincoff AM; Spiess BD; Aronson S
    J Thorac Cardiovasc Surg; 2006 Mar; 131(3):686-92. PubMed ID: 16515924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bivalirudin, blood loss, and graft patency in coronary artery bypass surgery.
    Merry AF
    Semin Thromb Hemost; 2004 Jun; 30(3):337-46. PubMed ID: 15282656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preemptive use of bivalirudin for urgent on-pump coronary artery bypass grafting in patients with potential heparin-induced thrombocytopenia.
    Dyke CM; Koster A; Veale JJ; Maier GW; McNiff T; Levy JH
    Ann Thorac Surg; 2005 Jul; 80(1):299-303. PubMed ID: 15975385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery.
    Merry AF; Raudkivi PJ; Middleton NG; McDougall JM; Nand P; Mills BP; Webber BJ; Frampton CM; White HD
    Ann Thorac Surg; 2004 Mar; 77(3):925-31; discussion 931. PubMed ID: 14992900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study.
    Dyke CM; Smedira NG; Koster A; Aronson S; McCarthy HL; Kirshner R; Lincoff AM; Spiess BD
    J Thorac Cardiovasc Surg; 2006 Mar; 131(3):533-9. PubMed ID: 16515902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot, prospective evaluation of a direct thrombin inhibitor, bivalirudin (Angiomax), in patients undergoing lower extremity bypass.
    Kashyap VS; Bishop PD; Bena JF; Rosa K; Sarac TP; Ouriel K
    J Vasc Surg; 2010 Aug; 52(2):369-74. PubMed ID: 20478686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Off-pump coronary artery bypass with bivalirudin for patients with heparin-induced thrombocytopenia or antiplatelet factor four/heparin antibodies.
    Dyke CM; Aldea G; Koster A; Smedira N; Avery E; Aronson S; Spiess BD; Lincoff AM
    Ann Thorac Surg; 2007 Sep; 84(3):836-9. PubMed ID: 17720385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial.
    Koster A; Dyke CM; Aldea G; Smedira NG; McCarthy HL; Aronson S; Hetzer R; Avery E; Spiess B; Lincoff AM
    Ann Thorac Surg; 2007 Feb; 83(2):572-7. PubMed ID: 17257990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical experience with the use of bivalirudin in a large population undergoing endovascular abdominal aortic aneurysm repair.
    Stamler S; Katzen BT; Tsoukas AI; Baum SZ; Diehm N
    J Vasc Interv Radiol; 2009 Jan; 20(1):17-21. PubMed ID: 19026565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct thrombin inhibition appears to be a safe and effective anticoagulant for percutaneous bypass graft interventions.
    Kao J; Lincoff AM; Topol EJ; Madrid A; J Price M; Sawhney N; Teirstein PS
    Catheter Cardiovasc Interv; 2006 Sep; 68(3):352-6. PubMed ID: 16892428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bivalirudin for patients with acute coronary syndromes.
    Stone GW; McLaurin BT; Cox DA; Bertrand ME; Lincoff AM; Moses JW; White HD; Pocock SJ; Ware JH; Feit F; Colombo A; Aylward PE; Cequier AR; Darius H; Desmet W; Ebrahimi R; Hamon M; Rasmussen LH; Rupprecht HJ; Hoekstra J; Mehran R; Ohman EM;
    N Engl J Med; 2006 Nov; 355(21):2203-16. PubMed ID: 17124018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of bivalirudin on outcomes after percutaneous coronary revascularization with drug-eluting stents.
    Feldman DN; Wong SC; Gade CL; Gidseg DS; Bergman G; Minutello RM
    Am Heart J; 2007 Oct; 154(4):695-701. PubMed ID: 17892994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of patient outcomes with bivalirudin versus unfractionated heparin in percutaneous coronary intervention.
    Watson K; Seybert AL; Saul MI; Lee JS; Kane-Gill SL
    Pharmacotherapy; 2007 May; 27(5):647-56. PubMed ID: 17461699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bivalirudin, a bivalent, thrombin specific anticoagulant as an alternative to heparin in interventional procedures as an alternative to heparin in interventional procedures.
    Chew DP
    Hamostaseologie; 2002 Aug; 22(3):60-6. PubMed ID: 12215763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Bivalirudin for Anticoagulation in Adult Perioperative Cardiothoracic Practice.
    Erdoes G; Ortmann E; Martinez Lopez De Arroyabe B; Reid C; Koster A
    J Cardiothorac Vasc Anesth; 2020 Aug; 34(8):2207-2214. PubMed ID: 31521492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-hospital safety and effectiveness of bivalirudin in percutaneous peripheral interventions: data from a real-world registry.
    Shammas NW; Shammas GA; Jerin M; Dippel EJ; Shammas AN
    J Endovasc Ther; 2010 Feb; 17(1):31-6. PubMed ID: 20199263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bivalirudin.
    Warkentin TE; Greinacher A; Koster A
    Thromb Haemost; 2008 May; 99(5):830-9. PubMed ID: 18449412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bivalirudin during primary PCI in acute myocardial infarction.
    Stone GW; Witzenbichler B; Guagliumi G; Peruga JZ; Brodie BR; Dudek D; Kornowski R; Hartmann F; Gersh BJ; Pocock SJ; Dangas G; Wong SC; Kirtane AJ; Parise H; Mehran R;
    N Engl J Med; 2008 May; 358(21):2218-30. PubMed ID: 18499566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial).
    Lincoff AM; Bittl JA; Kleiman NS; Sarembock IJ; Jackman JD; Mehta S; Tannenbaum MA; Niederman AL; Bachinsky WB; Tift-Mann J; Parker HG; Kereiakes DJ; Harrington RA; Feit F; Maierson ES; Chew DP; Topol EJ;
    Am J Cardiol; 2004 May; 93(9):1092-6. PubMed ID: 15110198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.